Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of modified hollow fiber materials for removal of exotoxins produced by Escherichia coli from liquids, preferably blood and plasma, and their use for the treatment of concomitant diseases

一种大肠杆菌、纤维材料的技术，应用在血液循环处理、滤血、化学仪器和方法等方向，能够解决昂贵治疗费用等问题

Active Publication Date: 2016-12-21
SAFE BT INC
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This plasma exchange requires approximately 12 liters of plasma per patient, which requires a large number of donors and may be associated with a higher risk of other infections and allergies
In addition, plasma exchange therapy involves expensive treatment costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1: Removal of Shiga toxins by selective adsorption under in vitro conditions

[0050] A) Preparation of Shiga toxin

[0051] To prepare and enrich Shiga toxin, E. coli EHEC O104 was cultured overnight in a medium containing: NaCl (10 g / L), tryptone (Triptone, 10 g / L, Becton Dickinson) and yeast extract (5 g / L, Becton Dickinson). After centrifugation of the suspension (200 g, 30 min) and sedimentation of E. coli, a Shiga toxin 2 (Stx2) highly concentrated supernatant was obtained. The concentration of Stx2 corresponds to an "optical density" (OD450 / 620) of 4.06. This value was determined by using a dedicated ELISA detection kit (Premier EHEC, Meridian Bioscience).

[0052] B) Perfusion of Shiga toxin solution through S.A.F.E.bt adsorption device (B.BraunMelsungen AG)

[0053] An aliquot of the supernatant containing Stx2 diluted 1:2 was obtained according to the method described in A). The solution was perfused separately through the S.A.F.E.bt sorption uni...

Embodiment 2

[0056]Example 2: Preventive treatment of EHEC

[0057] The present case is a 17-year-old boy who suffered from bloody diarrhea for 3 days and whose stool was positive for EHEC. Hemolytic uremic syndrome (HUS) was not confirmed at the time. Four days after his first episode of diarrhea (on June 21, 2011), the patient was treated with the SAFE-system. The duration of treatment is 2 hours. The treatment did not produce any complications and was well tolerated by the patient. After treatment and in the following days, diarrhea did not occur. Shiga toxin was no longer detectable in the stool, and the patient could be discharged after a few days without showing any symptoms. At a follow-up examination on July 7, 2011, no EHEC bacteria were detected and the patient's results were normal.

Embodiment 3

[0058] Example 3: Therapeutic Treatment of EHEC / HUS Syndrome

[0059] This case is a 74-year-old woman from Hannover. The patient was in good health and had sudden onset (nonbloody) diarrhea that lasted for 4 days. On June 16, 2011, she was transferred from the hospital in Lehrte to the Oststadt-Heidehaus clinic in Hannover because of acute renal failure with coagulation-like HUS syndrome.

[0060] On admission on June 16, 2011, the patient was conscious and responsive. However, the patient was "anxious and forgetful," according to the admission physician's description of his neurological condition. On admission, the patient's laboratory parameters showed a creatine concentration of 7.2 mg / dl, a urea concentration of 220 mg / dl, a platelet concentration of 115 T / ml, and a lactate dehydrogenase of 1460 U / L.

[0061] Between June 16, 2011, and June 22, 2011, the patient was on acute dialysis in the intensive care unit and, due to EHEC-HUS syndrome that was documented during th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to chemically modified hollow fiber materials for the in vitro removal of exotoxins produced by pathogenic Escherichia coli from protein-containing fluids, especially blood or plasma, and their use in the treatment of patients suffering from diseases Use, the disease being caused eg by Enterohaemorrhagic Escherichia coli bacteria (EHEC infection) or other pathogenic Escherichia coli, such as enterotoxic Escherichia coli (ETEC) or enteroaggregative Escherichia coli (EAEC).

Description

technical field [0001] The present invention relates to chemically modified hollow fiber materials for the in vitro removal of exotoxins produced by pathogenic E. Use in patients with diseases caused by Bacillus bacteria (EHEC infection) or other pathogenic Escherichia coli such as enterotoxic Escherichia coli (ETEC) or enteroaggregative Escherichia coli (EAEC). Background technique [0002] Shiga toxin (also known as Shiga-like or Vero toxin) produced by Escherichia coli (STEC bacteria) was described in 1977 (Konowalchuk et al., Infect Immun, 1977, 18:775-779), but it was not described until 1983. Linked to hemolytic uremic syndrome (HUS) (Karmali et al., Lancet, 1983, 2:619-20). Since then, STEC infection has been shown to be a major cause of acute renal failure, especially in children. It has been recognized until now that once HUS has developed, its treatment is very difficult (Thorpe CM, Food Safety CID. 2004, 38: 1298-1303). Therefore, research efforts have mainly f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): B01J41/04B01J41/12B01J47/12A61M1/36B01J20/28B01J20/32B01D69/08B01D67/00
CPCB01J41/04B01J20/28023B01J20/3248B01J20/3272B01D67/0093B01D2323/38A61M1/3679B01D69/08F04C2270/0421B01J41/13B01J47/127A61M1/3403A61M1/34B01D71/78A61M1/36B01D67/00931
Inventor D·赛德尔B·R·耶格尔
Owner SAFE BT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com